

In the Claims

Claims 1-49 (Previously Cancelled)

50. (Previously Amended) A method for treating or preventing autoimmune disease, human T-cell leukemia, transplant rejection or graft-versus-host disease, allergy or an infectious disease in a subject, comprising administering to the subject an effective amount of a peptide which:

- (i) comprises the sequence shown as SEQ ID No. 2; and
- (ii) has fewer than 40 amino acids.

51. (Currently Amended) The method according to claim 50 wherein the peptide may be further characterized as part of a fusion protein, ~~wherein the peptide acts as an immunomodulator.~~

52. (Previously Added) A method according to claim 50 for treating autoimmune disease, human T-cell leukemia, transplant rejection or graft-versus-host disease or allergy.

53. (Previously Added) A method according to claim 50, wherein the disease is not cholera or enterotoxin-mediated.

54. (Previously Added) A method according to claim 50, wherein the peptide comprises the sequence shown in SEQ ID NO 3, SEQ ID NO 4 or SEQ ID NO 5.

55. (Previously Added) A method according to claim ⁵⁰ 1, wherein the peptide is selected from the group consisting of SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4 and SEQ ID NO 5.

56. (New) The method according to claim 50 wherein the peptide acts as an immunomodulator.